Sanofi-Aventis CEO Chris Viehbacher said he wants to improve research and development without opening another R&D center, which he said can be resource-intensive and unproductive. He also wants the company to co-invest with private-equity firms in startups as well as ramp up collaboration and acquisition to promote innovation in various diseases. The R&D strategy was unveiled as Viehbacher took over as CEO of Genzyme, which Sanofi acquired for $20.1 billion.

Related Summaries